Online inquiry

IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3077MR)

This product GTTS-WQ3077MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3077MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8598MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ3628MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ8606MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ6066MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ5439MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ4942MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ10877MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ893MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW